Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). حسب Mingee Choi (15250732)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. حسب Mingee Choi (15250732)

الموضوعات:

Anthropometric characteristics of smokers and non-smokers. حسب Prasanna Herath (20714794)

الموضوعات:

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. حسب Mingee Choi (15250732)

الموضوعات:

Respiratory clinical characteristics of smokers and non-smokers. حسب Prasanna Herath (20714794)

الموضوعات:

Lung function parameters between smokers and non-smokers. حسب Prasanna Herath (20714794)

الموضوعات:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. حسب Mingee Choi (15250732)

الموضوعات:

The table shows the significant and non-significant altered group with different parameters. حسب Ashraf Attia Mahmoud (21262201)

Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... حسب Mingee Choi (15250732)

الموضوعات:

General information of patient who diagnosis insomnia disorder (N = 518,119). حسب Mingee Choi (15250732)

الموضوعات:

Treatment at first diagnosis of insomnia disorder (%). حسب Mingee Choi (15250732)

الموضوعات:

Significantly Enriched Pathways. حسب Jiyong Zhang (2498740)

الموضوعات: